News

A patient with prostate cancer in the SECuRE trial treated with 2 cycles of 67Cu-SAR-bisPSMA at the 8GBq dose level has achieved undetectable prostate specific antigen levels.

Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.

Here is a look back at the FDA happenings from the month of November 2023.

A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.

Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.

Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.

Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.

The investigation follows reports of T-cell malignancies after treatment with chimeric antigen receptor T-cell immunotherapies.

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

More work is needed in the community oncology setting to improve barriers to care and enrollment in clinical trials which are often due to geographic location, awareness, and eligibility criteria.

Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Mark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.

CT-0525 is an ex vivo gene-modified autologous CAR-monocyte cellular therapy being evaluated for the treatment of HER2-overexpressing solid tumors.

Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

The potential of CTLA4 deletion as a strategy to improve chimeric antigen receptor T-cell efficacy was observed in a study published in Immunity.

A fast track designation has been granted to zotatifin with fulvestrant, and abemaciclib for adult patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

Nirogacestat is now an FDA-approved option for adult patients with progressing desmoid tumors who require systemic treatment.

The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.

The biologics license application seeking the approval of obe-cel as a potential therapeutic option in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.